{"organizations": [], "uuid": "608fa5aa26f83a4bcca81e488bced5bfe9d3f5c1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/23/globe-newswire-inspire-medical-systems-inc-announces-commencement-of-its-initial-public-offering.html", "country": "US", "domain_rank": 767, "title": "Inspire Medical Systems, Inc. Announces Commencement of its Initial Public Offering", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T15:00:00.000+03:00", "replies_count": 0, "uuid": "608fa5aa26f83a4bcca81e488bced5bfe9d3f5c1"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/23/globe-newswire-inspire-medical-systems-inc-announces-commencement-of-its-initial-public-offering.html", "ord_in_thread": 0, "title": "Inspire Medical Systems, Inc. Announces Commencement of its Initial Public Offering", "locations": [], "entities": {"persons": [{"name": "stifel", "sentiment": "none"}], "locations": [{"name": "minneapolis", "sentiment": "none"}], "organizations": [{"name": "inspire medical systems, inc", "sentiment": "neutral"}, {"name": "new york stock exchange", "sentiment": "none"}, {"name": "wells fargo securities", "sentiment": "none"}, {"name": "guggenheim securities", "sentiment": "none"}, {"name": "goldman sachs & co", "sentiment": "none"}, {"name": "bofa merrill lynch", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MINNEAPOLIS, April 23, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that it has commenced an initial public offering of 5,000,000 shares of its common stock. Inspire also expects to grant the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock. The initial public offering price is expected to be between $14.00 and $16.00 per share. All shares of common stock to be sold in the proposed offering will be sold by Inspire. Inspire has been approved to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.”\nBofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint book-running managers for the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-managers for the proposed offering.\nThe offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: dg.prospectus_requests@baml.com ; and from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com .\nA registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Inspire Medical Systems\nInspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.\nInspire Investor and Media Contact\nBob Yedid\nLifeSci Advisors\nbob@lifesciadvisors.com\n646-597-6989\nSource:Inspire Medical Systems, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/b831ded8-0d58-4501-9aee-8263db12c9c3", "https://www.globenewswire.com/Tracker?data=A7_HBlVpMc8tIQVEISiBJN4mcnkuwF5dXElTAChOfXctMo3Mku4cVg8cFNXE0B5yfXKyAL_lU_2V_Jng62OOd_YizR0o0wrtixnBRpts4nc=", "https://www.globenewswire.com/Tracker?data=UvWyNB1D0vYQ6Ia92DtiwZiVVdH4sqjeIiNFC8gEPHl3bcrJkio43vGDbnzcdos4p9f-9butbYrVgEplT6F8Zf-qe3EY1XPvakiZ9MfEUV1cbgDXnPlNYQqfT0VoUtwz", "https://www.globenewswire.com/Tracker?data=FnkoxlrXB43DU5bQRkDmGJmTxXNER1BhtXSGFUPpysL4fZmYlW6XhUBhxccI1pqh05r_y-ogFPGM7IeFMxl2qKZ8jxr9fpL6aArV9W2XCaYHaOYox7z3Q_61H5LJnM7d"], "published": "2018-04-23T15:00:00.000+03:00", "crawled": "2018-04-23T18:00:24.003+03:00", "highlightTitle": ""}